October 25, 2014 12:30 AM ET

Life Sciences Tools and Services

Company Overview of Personalis, Inc.

Company Overview

Personalis, Inc. provides human genome analysis services for clinical medicine. It offers genome sequencing and interpretation services for research and medical communities. The company was incorporated in 2011 and is based in Palo Alto, California with a subsidiary operation in the United Kingdom.

530 Lytton Avenue

2nd Floor

Palo Alto, CA 94301

United States

Founded in 2011

Key Executives for Personalis, Inc.

Co-Founder
Co-Founder
Co-Founder
Co-Founder
Compensation as of Fiscal Year 2014.

Personalis, Inc. Key Developments

Personalis, Inc. Introduces New Services for Cancer Research and Clinical Trials

Personalis, Inc. announced it is launching an expanded portfolio of cancer research solutions based on its ACE (Accuracy and Content Enhanced) sequencing, informatics and content technology platform. Scientists from Personalis presented the new portfolio of cancer research solutions this weekend to attendees at the 2014 American Society of Human Genetics Annual Meeting taking place through Wednesday in San Diego. The ACE Exome for Cancer provides data from the common gene set in the broader context of more than 8,000 medically related genes with augmented coverage, and 20,000 genes overall. The ACE Extended Cancer Panel targets the same broad cancer gene set, but achieves over 500x average sequencing coverage, for optimum sensitivity to alleles from rare cell subpopulations. Personalis offers this end-to-end service starting with a broad range of sample types, including FFPE blocks, Fine Needle Aspirates, core biopsies and fresh frozen tissue. By combining DNA and RNA analysis, Personalis provides a comprehensive tumor genomic profile. DNA and RNA assays are matched to cover the same gene sets, either at the exome level or the panel level. Personalis' cancer data analysis pipeline integrates the DNA and RNA results, providing a more comprehensive understanding than would be possible from either independently. This includes detection of fusion transcripts and allelic expression, as well as gene expression. None of these would be well reported with DNA analysis alone.

Personalis Launches Third Generation ACE Clinical Exome(TM) Test

Personalis, Inc. announced the launch of its newly enhanced ACE Clinical Exome(TM) Test for inherited genetic disease. The new test incorporates advances in the company's assay design, an extensive variant-review process, and the involvement of the company's world-class clinical team. The ACE Clinical Exome Test is based on a full exome, targeting essentially all human genes. Of these, Personalis augments the coverage of more than 8,000 medically associated genes, beginning with 4,600 genes identified by the International Collaboration for Clinical Genomics as being related to Mendelian Disease. Personalis then adds genes that have been more recently associated with Mendelian conditions, as well as genes determined likely to have as-yet undiscovered Mendelian associations. The medically associated gene set includes more than 1,200 genes linked to cancer, and hundreds identified as relevant to pharmacogenomics by PharmGKB(TM), the leading pharmacogenomics database. Greater than 6,000 of the augmented genes in the ACE Clinical Exome Test are finished by Personalis (>99% of exonic bases at >=20X coverage), more than any other commercial test. While early exomes for research discovery were designed to capture just the coding sequences of genes, it has long been recognized that medically reportable content extends beyond the coding regions. Personalis has extended the concept of a 'clinical exome' to capture those disease-associated non-coding regions. The ACE Clinical Exome Test provides coverage for a large number of medically reportable variants in untranslated regions (UTRs), introns and promoter regions.

Personalis, Inc. Wins U.S Department of Veterans Affairs Contract for Clinical Exome Testing Services for Genetic Disorders

Personalis, Inc. announced that the company has been awarded a contract to provide ACE Clinical Exome(TM) testing for genetic disorders by the U.S Department of Veterans Affairs (VA). To accurately identify the causes of specific patients' genetic disorders, the VA will use the Personalis ACE Clinical Exome Test, which contains content and features not found in conventional exome sequencing tests. The ACE Clinical Exome Test combines enhanced whole-exome sequencing, including additional coverage for more than 8,000 genes related to disease, coverage of medically important non-coding regions, with genome-wide structural variant detection, and a sophisticated analysis and interpretation process to increase diagnostic yield.

Similar Private Companies By Industry

Company Name Region
MS Card Central Corp. United States
PNA Innovations, Inc. United States
American Association for Bronchology and Interventional Pulmonology United States
West Coast Clinical Trials, LLC United States
Pall Life Sciences Puerto Rico, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Personalis, Inc., please visit www.personalis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.